Azitra Inc (AZTR) Q1 2025 Earnings Report

Azitra Inc reported a Q1 2025 results profile dominated by preclinical R&D and administrative spend with no revenue recognized. Net loss reached approximately $3.068 billion, driven primarily by R&D expense of $1.251 billion and G&A expense of $1.850 billion, yielding an operating loss of $3.100 billion and an EBITDA of negative $3.100 billion. The quarter also featured a modest net other income contribution of about $31.9 million, largely insufficient to offset the operating burn. The company ends the period with about $3.21 million in cash and equivalents and a negative free cash flow of approximately $3.10 million for the quarter, highlighting a significant liquidity challenge for a preclinical biotechnology company reliant on ongoing financing. On the balance sheet, Azitra shows a conservative leverage profile (total liabilities ~$1.5 million; total stockholders’ equity ~$4.41 million) and a cash-to-debt framework that remains favorable due to the very small debt load relative to cash. The reported YoY and QoQ metric deltas for operating income and net income indicate a deteriorating base versus the prior year, though some QoQ improvements in operating income are recorded. Absent a defined near-term revenue inflection or milestone-driven partnerships, Azitra’s near-term investment thesis hinges on successful progress of its ATR-led dermatology programs and the ability to secure follow-on financing to sustain development timelines.